Pharsight

Drug Patents Expiring in 2016

1. Aggrastat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5733919 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage

AGGRASTAT family patents

Family Patents

2. Epivir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using LAMIVUDINE ingredient

Market Authorisation Date: 17 November, 1995

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

EPIVIR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Liptruzet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5969156 ORGANON Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Jul, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 03, 2016

Drugs and Companies using ATORVASTATIN CALCIUM; EZETIMIBE ingredient

Market Authorisation Date: 03 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LIPTRUZET family patents

Family Patents

4. Lonsurf patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5744475 TAIHO ONCOLOGY Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
Mar, 2016

(8 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026
New Indication(I-794) Feb 22, 2022
New Chemical Entity Exclusivity(NCE) Sep 22, 2020

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if...

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

5. Nexium 24hr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5900424 ASTRAZENECA LP Omeprazole magnesium salt form
May, 2016

(8 years ago)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 23 November, 2015

Treatment: Treatment of frequent heartburn by administering a gastric acid reducer

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of NEXIUM 24HR before it's drug patent expiration?
More Information on Dosage

NEXIUM 24HR family patents

Family Patents

6. Revlimid patents expiration

Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288415 BRISTOL MYERS SQUIBB Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione
Jul, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-131) Feb 22, 2024
Orphan Drug Exclusivity(ODE-241) May 28, 2026
Orphan Drug Exclusivity(ODE-245) May 28, 2026
New Indication(I-706) Feb 17, 2018
New Indication(I-796) May 28, 2022
New Indication(I-797) May 28, 2022
Orphan Drug Exclusivity(ODE-49) Jun 05, 2020
Orphan Drug Exclusivity(ODE-88) Feb 17, 2022
New Indication(I-672) Jun 05, 2016
Orphan Drug Exclusivity(ODE) Jun 05, 2020
New Strength(NS) Jun 05, 2016

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 21 December, 2011

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage

REVLIMID family patents

Family Patents

7. Signifor Lar Kit patents expiration

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6225284 RECORDATI RARE Somatostatin peptides
Jun, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-268) Jun 29, 2025
New Indication(I-785) Jun 29, 2021
Orphan Drug Exclusivity(ODE) Dec 15, 2021
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
New Product(NP) Dec 15, 2017
Orphan Drug Exclusivity(ODE-81) Dec 15, 2021

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 29 June, 2018

Treatment: Method of treating disorders with an etiology comprising or associated with excess gh-secretion

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

SIGNIFOR LAR KIT family patents

Family Patents

8. Triumeq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-294) Jun 15, 2026
Pediatric Exclusivity(PED) Dec 15, 2026
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

NCE-1 date: 15 December, 2025

Market Authorisation Date: 22 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage

TRIUMEQ family patents

Family Patents

9. Varithena patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE40640 PROVENSIS Injectable microfoam containing a sclerosing agent
Oct, 2016

(7 years ago)

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 21 December, 2017

Treatment: A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the ...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VARITHENA family patents

Family Patents